Durvalumab + Cisplatin + Carboplatin + Etoposide
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-stage Small Cell Lung Cancer
Conditions
Extensive-stage Small Cell Lung Cancer
Trial Timeline
Nov 11, 2021 → Jan 2, 2025
NCT ID
NCT04774380About Durvalumab + Cisplatin + Carboplatin + Etoposide
Durvalumab + Cisplatin + Carboplatin + Etoposide is a phase 3 stage product being developed by AstraZeneca for Extensive-stage Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04774380. Target conditions include Extensive-stage Small Cell Lung Cancer.
What happened to similar drugs?
0 of 6 similar drugs in Extensive-stage Small Cell Lung Cancer were approved
Approved (0) Terminated (1) Active (5)
🔄Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated)Bristol Myers SquibbPhase 3
🔄BMS-986489 (BMS-986012+Nivolumab) + Atezolizumab + Carboplatin + EtoposideBristol Myers SquibbPhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04774380 | Phase 3 | Completed |
| NCT04870112 | Phase 1 | Terminated |
Competing Products
20 competing products in Extensive-stage Small Cell Lung Cancer